Poseida Therapeutics Inc. (PSTX): Price and Financial Metrics

Poseida Therapeutics Inc. (PSTX): $2.02

0.02 (+1.00%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

B

Add PSTX to Watchlist
Sign Up

PSTX Price/Volume Stats

Current price $2.02 52-week high $4.27
Prev. close $2.00 52-week low $1.54
Day low $1.95 Volume 641,400
Day high $2.07 Avg. volume 712,730
50-day MA $3.20 Dividend yield N/A
200-day MA $2.67 Market Cap 194.91M

PSTX Stock Price Chart Interactive Chart >


Poseida Therapeutics Inc. (PSTX) Company Bio


Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in 2014 and is headquartered in San Diego, CA.


PSTX Latest News Stream


Event/Time News Detail
Loading, please wait...

PSTX Latest Social Stream


Loading social stream, please wait...

View Full PSTX Social Stream

Latest PSTX News From Around the Web

Below are the latest news stories about POSEIDA THERAPEUTICS INC that investors may wish to consider to help them evaluate PSTX as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning!

William White on InvestorPlace | December 11, 2023

Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor (CAR)-T therapy candidate. The Company is investigating P-BCMA-ALLO1 in partnership with Roche for the treatment of relapsed/refractory multiple myeloma

Yahoo | December 10, 2023

Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare

The article embarks on a transformative journey through the biopharmaceutical frontier, where the listed companies stand as titans reshaping healthcare norms.

Yiannis Zourmpanos on InvestorPlace | November 17, 2023

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the third quarter ended September 30, 2023.

Yahoo | November 9, 2023

Poseida Therapeutics to Present at Two Upcoming Investor Conferences

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company will participate in the following upcoming investor conferences in November:

Yahoo | November 7, 2023

Read More 'PSTX' Stories Here

PSTX Price Returns

1-mo -35.05%
3-mo -32.89%
6-mo -3.81%
1-year -29.12%
3-year -78.04%
5-year N/A
YTD -39.88%
2023 -36.60%
2022 -22.17%
2021 -37.92%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!